文献速递产科

足月初产妇产后缩宫素剂量与产后出血结局的相关性

Association of postpartum oxytocin dose and postpartum bleeding outcomes in nulliparous patients at term.
PubMed 文献 · Am J Obstet Gynecol · 2025-01-30

本研究为多中心随机对照试验的二次分析,纳入2404例足月单胎初产妇,比较产后高剂量缩宫素(80国际单位)与低剂量(10-30国际单位)方案下产后出血及需额外干预的发生率。结果显示高剂量组主要复合结局的调整比值比更低(aOR 0.53,95%CI 0.34-0.82),主要由产后出血几率降低驱动(aOR 0.44,95%CI 0.27-0.72)。作者认为高剂量产后缩宫素与较低的产品后出血率相关,但需未来多中心试验进一步验证。

要点

  • 高剂量产后缩宫素组主要复合结局调整比值比为0.53(95%CI 0.34-0.82),低于低剂量组。
  • 高剂量组产后出血调整比值比为0.44(95%CI 0.27-0.72),低于低剂量组。
  • 剂量效应分析示中剂量OR 0.57(95%CI 0.41-0.80)、高剂量OR 0.39(95%CI 0.25-0.61),交互P<.01。

核心结论

  • 高剂量产后缩宫素与较低的产品后出血率相关,效果在阴道分娩和剖宫产中似乎一致(原文注明主要试验中剖宫产者第二产程已给缩宫素)。
  • 鉴于缩宫素全球广泛使用且成本较低,作者认为未来需开展多中心试验研究产后缩宫素剂量。

研究设计与样本

  • 研究为多中心随机对照试验的二次分析,原试验纳入2404例足月单胎初产妇,研究第二产程立即用力与延迟用力(2014年5月至2017年12月)。
  • 产后缩宫素方案从6个参与中心获取,分为高剂量(80国际单位/500 mL,胎盘娩出后1-4小时内输注)和低剂量(10-30国际单位/500-1000 mL,1-4小时内输注)。
  • 主要结局为初始产后缩宫素后使用宫缩剂、任何输血和产后出血的复合结局;产后出血定义为阴道分娩后估计失血量>500 mL、剖宫产术后>1000 mL。

主要发现

  • 全部2404例患者纳入分析:高剂量组455例(19%),低剂量组1949例(81%)。
  • 高剂量组患者更可能年轻、非裔美国人、肥胖、暴露于硫酸镁并实现阴道分娩。
  • 与低剂量缩宫素相比,高剂量组主要复合结局调整比值比为0.53(95%CI 0.34-0.82),主要由产后出血几率降低驱动(调整比值比0.44,95%CI 0.27-0.72)。
  • 其他次要结局频率在高剂量组较低,但调整后几率无显著差异。
  • 按总剂量分析:中剂量(30国际单位)主要复合结局比值比0.57(95%CI 0.41-0.80),高剂量(80国际单位)比值比0.39(95%CI 0.25-0.61),交互P<.01;缩宫素剂量对主要结局的影响不因分娩方式而异(交互P=.35)。

关键数值与推荐

  • 高剂量产后缩宫素方案为80国际单位/500 mL,胎盘娩出后1-4小时内输注;低剂量为10-30国际单位/500-1000 mL,1-4小时内输注。
  • 产后出血定义为阴道分娩后估计失血量>500 mL,剖宫产术后>1000 mL。
  • 主要复合结局包括初始产后缩宫素后使用宫缩剂、任何输血和产后出血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postpartum hemorrhage is a leading cause of morbidity and mortality. The use of prophylactic oxytocin in the third stage of labor is globally accepted as standard of care for the prevention of postpartum hemorrhage; however, the most effective dose of oxytocin is unknown. While studies suggest a possible benefit of higher doses of postpartum prophylactic oxytocin, results are inconclusive, and data are limited. OBJECTIVE: Our objective was to compare rates of postpartum hemorrhage and the need for additional postpartum hemorrhage interventions between high-dose (80 international units) and low-dose (10-30 international units) postpartum oxytocin regimens. STUDY DESIGN: Secondary analysis of a multicenter randomized control trial of 2404 nulliparous women with term singleton pregnancies that investigated immediate vs delayed pushing in women in the second stage of labor (5/2014-12/2017). Postpartum oxytocin regimens were ascertained from each of the 6 participating centers and categorized as high-dose (80 international units/500 mL over 1-4 hours after placental delivery) and low-dose (10-30 international units/500-1000 mL over 1-4 hours). The primary outcome was a composite of uterotonic use after initial postpartum oxytocin, any blood transfusion, and postpartum hemorrhage. Postpartum hemorrhage was defined as estimated blood loss >500 mL after vaginal delivery and >1000 mL after cesarean delivery. Secondary outcomes included individual composite components and select bleeding outcomes. Logistic regression using covariates identified as significant in parsimonious modeling were used to estimate adjusted odds ratios and 95% confidence intervals using the low-dose group as the reference. Dose effect analysis by total dose and effect modification by mode of delivery were also performed. RESULTS: All 2404 patients from the primary trial were included: 455 (19%) in the high-dose group and 1949 (81%) in the low-dose group. Women in the high-dose group were more likely to be younger, African American, obese, have magnesium sulfate exposure, and achieve vaginal delivery. Compared to low-dose oxytocin, patients receiving high-dose oxytocin had lower odds of the primary composite outcome (adjusted odds ratio 0.53, 95% confidence interval 0.34-0.82), primarily driven by decreased odds of postpartum hemorrhage (adjusted odds ratio 0.44, 95% confidence interval 0.27-0.72). While frequencies of other secondary outcomes were lower in the high-dose group, there was no significant difference in odds of these outcomes after adjustment. Analysis of dose effect by total dose between low- (10-20 international units), moderate- (30 international units), and high- (80 international units) dose oxytocin revealed a decreased odds of the primary composite outcome with moderate- and high-dose (moderate-dose: odds ratio 0.57, 95% confidence interval 0.41-0.80; high-dose: odds ratio 0.39, 95% confidence interval 0.25-0.61; interaction P<.01).The effect of oxytocin dose on the primary outcome did not differ by delivery mode (interaction P=.35). CONCLUSION: High-dose postpartum oxytocin was associated with lower rates of postpartum hemorrhage than lower oxytocin doses. Results appeared consistent for both vaginal and cesarean deliveries (at second stage given primary trial). Given the widespread use of oxytocin globally and its relatively low cost, future multicenter trials of postpartum oxytocin dose are warranted.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shea AE, Woolfolk CL, Cahill AG, et al. Association of postpartum oxytocin dose and postpartum bleeding outcomes in nulliparous patients at term. Am J Obstet Gynecol. 2025. PMID: 39892837. doi:10.1016/j.ajog.2025.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。